Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity

Background: Obesity is often associated with nonalcoholic fatty liver disease (NAFLD), which refers to a large spectrum of hepatic lesions including fatty liver, nonalcoholic steatohepatitis (NASH) and cirrhosis. Different investigations showed or suggested that obesity and NAFLD are able to increase the risk of hepatotoxicity of different drugs. Some of these drugs could induce more frequently an acute hepatitis in obese individuals whereas others could worsen pre-existing NAFLD. Aim: The main objective of the present review was to collect the available information regarding the role of NAFLD as risk factor for drug-induced hepatotoxicity. For this purpose, we performed a data-mining analysis using different queries including drug-induced liver injury (or DILI), drug-induced hepatotoxicity, fatty liver, nonalcoholic fatty liver disease (or NAFLD), steatosis and obesity. The main data from the collected articles are reported in this review and when available, some pathophysiological hypotheses are put forward. Relevance for patients: Drugs that could pose a potential risk in obese patients include compounds belonging to different pharmacological classes such as acetaminophen, halothane, methotrexate, rosiglitazone, stavudine and tamoxifen. For some of these drugs, experimental investigations in obese rodents confirmed the clinical observations and unveiled different pathophysiological mechanisms which could explain why these pharmaceuticals are particularly hepatotoxic in obesity and NAFLD. Other drugs such as pentoxifyl-line, phenobarbital and omeprazole might also pose a risk but more investigations are required to determine whether this risk is significant or not. Because obese people often take several drugs for the treatment of different obesity-related diseases such as type 2 diabetes, hyperlipidemia and coronary heart disease, it is urgent to identify the main pharmaceuticals that can cause acute hepatitis on a fatty liver background or induce NAFLD worsening.

[1]  I. Papet,et al.  Skeletal muscle wasting occurs in adult rats under chronic treatment with paracetamol when glutathione-dependent detoxification is highly activated. , 2014, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[2]  邱玉文.  Troglitazone , 2000 .

[3]  P. McNamara,et al.  Phenobarbital induction and acetaminophen hepatotoxicity: resistance in the obese Zucker rodent. , 1987, The Journal of pharmacology and experimental therapeutics.

[4]  R. Hultcrantz,et al.  Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. , 2007, Journal of hepatology.

[5]  S. Kaneko,et al.  Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis. , 2007, Internal medicine.

[6]  M. Rinella,et al.  A myriad of pathways to NASH. , 2012, Clinics in liver disease.

[7]  G. Labbe,et al.  Drug‐induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies , 2008, Fundamental & clinical pharmacology.

[8]  D. Crane,et al.  Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury , 2013, Laboratory Investigation.

[9]  G. Labbe,et al.  Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibiotic , 1988, Hepatology.

[10]  A. Loud,et al.  CORTISONE-INDUCED ALTERATIONS IN MITOCHONDRIAL FUNCTION AND STRUCTURE , 1968, The Journal of cell biology.

[11]  H. Uozaki,et al.  Therapeutic dose of acetaminophen as a possible risk factor for acute kidney injury: learning from two healthy young adult cases. , 2014, Internal medicine.

[12]  B. Fromenty,et al.  Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. , 2011, Clinics and research in hepatology and gastroenterology.

[13]  K. Lindor,et al.  A Pilot Trial of Pentoxifylline in Nonalcoholic Steatohepatitis , 2004, The American Journal of Gastroenterology.

[14]  M. Letizia,et al.  Drug-induced hepatic injury. , 1997, Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses.

[15]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[16]  J. Zucman‐Rossi,et al.  PNPLA3 gene in liver diseases. , 2016, Journal of hepatology.

[17]  J. Zhao,et al.  Protective effect of bicyclol on tetracycline-induced fatty liver in mice. , 2009, Toxicology.

[18]  M. Roden,et al.  Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease , 2013, Molecular and Cellular Endocrinology.

[19]  S. Kakar,et al.  Histological patterns in drug-induced liver disease , 2009, Journal of Clinical Pathology.

[20]  W. J. Boscardin,et al.  Identification of Risk Factors for Elevated Transaminases in Methotrexate Users Through an Electronic Health Record , 2014, Arthritis care & research.

[21]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[22]  Yun-Ching Chang,et al.  Mulberry anthocyanins inhibit oleic acid induced lipid accumulation by reduction of lipogenesis and promotion of hepatic lipid clearance. , 2013, Journal of agricultural and food chemistry.

[23]  J. Capeau,et al.  Hepatic molecular effects of rosiglitazone in human non‐alcoholic steatohepatitis suggest long‐term pro‐inflammatory damage , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[24]  Jie Zhang,et al.  A unifying ontology to integrate histological and clinical observations for drug-induced liver injury. , 2013, The American journal of pathology.

[25]  Svetlana K. Eden,et al.  Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. , 2012, AIDS research and human retroviruses.

[26]  Sung-Bae Kim,et al.  Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients. , 2016, Breast.

[27]  B. Fromenty,et al.  Acetaminophen‐induced liver injury in obesity and nonalcoholic fatty liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[28]  A. Mally,et al.  Role of drug-independent stress factors in liver injury associated with diclofenac intake. , 2013, Toxicology.

[29]  F. Capron,et al.  Excess weight risk factor for alcoholic liver disease , 1997, Hepatology.

[30]  M. Lazar,et al.  Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. , 2014, Cell metabolism.

[31]  G. Tarantino,et al.  A prospective study of acute drug‐induced liver injury in patients suffering from non‐alcoholic fatty liver disease , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[32]  A. Shaheen,et al.  Hepatitis C, alcohol abuse, and unintentional overdoses are risk factors for acetaminophen‐related hepatotoxicity , 2009, Hepatology.

[33]  Evan G. Williams,et al.  Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research. , 2015, Cell reports.

[34]  Qihong Huang,et al.  The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[35]  A. Sanyal,et al.  The Worsening Profile of Alcoholic Hepatitis in the United States. , 2016, Alcoholism, clinical and experimental research.

[36]  E. Schon,et al.  Alterations of Mitochondrial DNA in Liver Diseases , 2015 .

[37]  R. Kim,et al.  CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease , 2015, Drug Metabolism and Disposition.

[38]  Steven P. Larson,et al.  Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[39]  W. Hawkins,et al.  Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. , 2005, Journal of the American College of Surgeons.

[40]  J. Madura,et al.  Anesthetic Biotransformation and Renal Function in Obese Patients during and after Methoxyflurane or Halothane Anesthesia , 1975, Anesthesiology.

[41]  J. Finsterer,et al.  Drugs interfering with mitochondrial disorders , 2010, Drug and chemical toxicology.

[42]  G. Langman,et al.  Role of non‐alcoholic steatohepatitis in methotrexate‐induced liver injury , 2001, Journal of gastroenterology and hepatology.

[43]  J. N. van den Anker,et al.  Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen , 2016, Clinical Pharmacokinetics.

[44]  M. Czaja,et al.  Hepatocyte CYP2E1 Overexpression and Steatohepatitis Lead to Impaired Hepatic Insulin Signaling* , 2005, Journal of Biological Chemistry.

[45]  M. Trauner,et al.  Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)☆ , 2014, Biochimica et biophysica acta.

[46]  S. Davis,et al.  Effect of fasting and obesity in humans on the 6‐hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity , 1994, Clinical pharmacology and therapeutics.

[47]  F. Wright,et al.  Use of Pharmaco‐Metabonomics for Early Prediction of Acetaminophen‐Induced Hepatotoxicity in Humans , 2010, Clinical pharmacology and therapeutics.

[48]  S. Lakhani,et al.  Dose-dependent Acute Hepatitis Associated with Administration of High Dose Methotrexate , 1988, Human toxicology.

[49]  Mitchell R. McGill,et al.  A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen. , 2016, Toxicology and applied pharmacology.

[50]  N. Chalasani,et al.  An assessment by the Statin Liver Safety Task Force: 2014 update. , 2014, Journal of clinical lipidology.

[51]  S. Cole,et al.  Antiretroviral therapies associated with lipoatrophy in HIV-infected women. , 2007, AIDS patient care and STDs.

[52]  K. Pantazis,et al.  Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance , 2004, European journal of gastroenterology & hepatology.

[53]  L. Forman,et al.  Hepatic Failure in a Patient Taking Rosiglitazone , 2000, Annals of Internal Medicine.

[54]  A. P. Campello,et al.  Methotrexate: Studies on cellular metabolism. II—Effects on mitochondrial oxidative metabolism and ion transport , 1989, Cell biochemistry and function.

[55]  P. Chinnery,et al.  HIV Treatment and Associated Mitochondrial Pathology , 2014, Toxicologic pathology.

[56]  R. Steffensen,et al.  Activation of the complement system in human nonalcoholic fatty liver disease , 2009, Hepatology.

[57]  A. Karstaedt,et al.  A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  B. Hallén,et al.  Halothane‐Induced Liver Damage: An Analysis of the Material Reported to the Swedish Adverse Drug Reaction Committee, 1966–1973 , 1976, Acta anaesthesiologica Scandinavica.

[59]  R. Fontana,et al.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. , 2008, Gastroenterology.

[60]  T. Pawlik,et al.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Torbenson,et al.  Chronic intermittent hypoxia and acetaminophen induce synergistic liver injury in mice , 2009, Experimental physiology.

[62]  M. Ingelman-Sundberg,et al.  Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis , 1998, Hepatology.

[63]  T. Maeda,et al.  Halothane-induced cytotoxicity in isolated rat hepatocytes: an electron microscopic study. , 1993, In vivo.

[64]  B. Fromenty,et al.  Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity , 2011, The FEBS journal.

[65]  Shasha Zhang,et al.  Association Between Patatin-Like Phospholipase Domain Containing 3 Gene (PNPLA3) Polymorphisms and Nonalcoholic Fatty Liver Disease: A HuGE Review and Meta-Analysis , 2015, Scientific Reports.

[66]  J. Watelet,et al.  Toxicity of chronic paracetamol ingestion , 2007, Alimentary pharmacology & therapeutics.

[67]  M. Abdelmegeed,et al.  Cytochrome P450-2E1 promotes aging-related hepatic steatosis, apoptosis and fibrosis through increased nitroxidative stress. , 2016, Free radical biology & medicine.

[68]  V. Ratziu,et al.  Pharmacological agents for NASH , 2013, Nature Reviews Gastroenterology &Hepatology.

[69]  D. Vance,et al.  Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes. , 2005, Diabetes.

[70]  G. Ligabue,et al.  Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  M. Ahern,et al.  Methotrexate hepatotoxicity: What is the evidence? , 1998, Inflammation Research.

[72]  B. Neuschwander‐Tetri.  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.

[73]  D. Pessayre,et al.  High Doses of Stavudine Induce Fat Wasting and Mild Liver Damage without Impairing Mitochondrial Respiration in Mice , 2006, Antiviral therapy.

[74]  C. Knibbe,et al.  Impact of Obesity on Drug Metabolism and Elimination in Adults and Children , 2012, Clinical Pharmacokinetics.

[75]  J. Pessin,et al.  Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K ATP channels , 2012 .

[76]  Á. Valverde,et al.  Essential Role of Protein-tyrosine Phosphatase 1B in the Modulation of Insulin Signaling by Acetaminophen in Hepatocytes* , 2014, The Journal of Biological Chemistry.

[77]  A. J. Gandolfi,et al.  Suspected isoflurane hepatitis in an obese patient with a history of halothane hepatitis. , 1995, Anesthesiology.

[78]  E. Roeb,et al.  Complement factor C5 deficiency significantly delays the progression of biliary fibrosis in bile duct-ligated mice. , 2012, Biochemical and biophysical research communications.

[79]  E. Finkelstein,et al.  Annual medical spending attributable to obesity: payer-and service-specific estimates. , 2009, Health affairs.

[80]  Mark D. Johnson,et al.  Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants. , 2014, Toxicology and applied pharmacology.

[81]  M. Camilo,et al.  Tamoxifen-associated steatohepatitis--report of three cases. , 1995, Journal of hepatology.

[82]  D. Pessayre,et al.  Mitochondrial, Metabolic and Genotoxic Effects of Antiretroviral Nucleoside Reverse-Transcriptase Inhibitors , 2006 .

[83]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[84]  U. Veronesi,et al.  Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial , 2005, BMJ : British Medical Journal.

[85]  L. Misery,et al.  Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[86]  In-kyu Lee,et al.  Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin. , 2010, Journal of hepatology.

[87]  M. Nishino,et al.  Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. , 2003, AJR. American journal of roentgenology.

[88]  Tsutomu Suzuki,et al.  Antibiotic susceptibility of mammalian mitochondrial translation , 2005, FEBS letters.

[89]  K. King,et al.  Development of an in vitro cell culture model of hepatic steatosis using hepatocyte‐derived reporter cells , 2009, Biotechnology and bioengineering.

[90]  M. Wehling.  Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects , 2014, European Journal of Clinical Pharmacology.

[91]  M. Núñez,et al.  Clinical syndromes and consequences of antiretroviral‐related hepatotoxicity , 2010, Hepatology.

[92]  J. Jordán,et al.  Minocycline exerts uncoupling and inhibiting effects on mitochondrial respiration through adenine nucleotide translocase inhibition. , 2012, Pharmacological research.

[93]  N. Foudraine,et al.  Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases , 2000, International journal of STD & AIDS.

[94]  B. Sharma,et al.  Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non‐alcoholic steatohepatitis , 2006, Journal of gastroenterology and hepatology.

[95]  D. Pessayre,et al.  Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver , 2007, Journal of Pharmacology and Experimental Therapeutics.

[96]  D. Pessayre,et al.  Glucocorticoids inhibit mitochondrial matrix acyl-CoA dehydrogenases and fatty acid beta-oxidation. , 1997, The American journal of physiology.

[97]  U. Walker,et al.  Uridine supplementation antagonizes zalcitabine‐induced microvesicular steatohepatitis in mice , 2007, Hepatology.

[98]  Y. Ogawa,et al.  Tamoxifen-induced fatty liver in patients with breast cancer , 1998, The Lancet.

[99]  Joe Kesterson,et al.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.

[100]  S. Bang,et al.  Assessment of Substantial Liver Fibrosis by Real‐time Shear Wave Elastography in Methotrexate‐Treated Patients With Rheumatoid Arthritis , 2015, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[101]  T. Zeng,et al.  Inhibition of cytochrome P4502E1 by chlormethiazole attenuated acute ethanol-induced fatty liver. , 2014, Chemico-biological interactions.

[102]  B. Fromenty,et al.  Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. , 2011, Journal of hepatology.

[103]  R. Blouin,et al.  Effect of nutritional obesity on the induction of CYP2B enzymes following phenobarbital treatment. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[104]  D. Kuritzkes,et al.  Higher-Than-Expected Rates of Lactic Acidosis Among Highly Active Antiretroviral Therapy-Treated Women in Botswana: Preliminary Results from a Large Randomized Clinical Trial , 2007, Journal of acquired immune deficiency syndromes.

[105]  J. Solís-Herruzo,et al.  Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice , 2007, Hepatology.

[106]  G. Labbe,et al.  Prediction of Liver Injury Induced by Chemicals in Human With a Multiparametric Assay on Isolated Mouse Liver Mitochondria , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[107]  N. Chalasani,et al.  Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis , 2003, Hepatology.

[108]  G. Labbe,et al.  Effects of various tetracycline derivatives on in vitro and in vivo beta-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, and mortality in mice. , 1991, Biochemical pharmacology.

[109]  G. Marchesini,et al.  Obesity-associated liver disease. , 2008, The Journal of clinical endocrinology and metabolism.

[110]  Q. Anstee,et al.  The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2 , 2015, Seminars in Liver Disease.

[111]  B. Neuschwander‐Tetri,et al.  Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. , 2003, Journal of hepatology.

[112]  P. Beaune,et al.  EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS , 2010 .

[113]  Guolin Li,et al.  Proteomic profile of carbonylated proteins in rat liver: Discovering possible mechanisms for tetracycline‐induced steatosis , 2015, Proteomics.

[114]  B. Fromenty,et al.  Drug-Induced Inhibition of Mitochondrial Fatty Acid Oxidation and Steatosis , 2013, Current Pathobiology Reports.

[115]  V. de Lédinghen,et al.  Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. , 2010, Journal of hepatology.

[116]  D. Pessayre,et al.  Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug‐induced steatosis in mice , 2003, Hepatology.

[117]  A. R. Pearce,et al.  Subcellular localization of rat CYP2E1 impacts metabolic efficiency toward common substrates. , 2015, Toxicology.

[118]  M. Leverkus,et al.  Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation , 2012, AIDS.

[119]  F. Damiano,et al.  Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis. , 2016, Biochimica et biophysica acta.

[120]  D. Rockey,et al.  The mitochondria-targeted antioxidant MitoQ attenuates liver fibrosis in mice. , 2016, International journal of physiology, pathophysiology and pharmacology.

[121]  S. R. Marana,et al.  H2O2 release from the very long chain acyl-CoA dehydrogenase , 2015, Redox biology.

[122]  N. Chalasani,et al.  Chronic liver injury induced by drugs: a systematic review , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[123]  R. Bataller,et al.  Alcoholic and non-alcoholic steatohepatitis. , 2014, Experimental and molecular pathology.

[124]  M. Feinglos,et al.  Pilot Study of Caffeine Abstinence for Control of Chronic Glucose in Type 2 Diabetes. , 2012, Journal of caffeine research.

[125]  Z. Madar,et al.  Nutritional lipid-induced oxidative stress leads to mitochondrial dysfunction followed by necrotic death in FaO hepatocytes. , 2009, Nutrition.

[126]  Soo-Hyun Park,et al.  New role of irisin in hepatocytes: The protective effect of hepatic steatosis in vitro. , 2015, Cellular signalling.

[127]  A. Earnest,et al.  Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis. , 2013, World journal of hepatology.

[128]  C. Stephens,et al.  Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. , 2014, Gastroenterology.

[129]  C. Postic,et al.  Cross-regulation of hepatic glucose metabolism via ChREBP and nuclear receptors. , 2011, Biochimica et biophysica acta.

[130]  F. Gonzalez,et al.  Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. , 2012, Journal of hepatology.

[131]  D. Pessayre,et al.  Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. , 2006, Mitochondrion.

[132]  Justina J. Sam,et al.  Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: A nationwide analysis , 2008, Hepatology.

[133]  C. Michet,et al.  Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. , 2004, The Journal of rheumatology.

[134]  H. Tsukamoto,et al.  Ethanol‐induced liver fibrosis in rats fed high fat diet , 1986, Hepatology.

[135]  Lang Li,et al.  Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. , 2003, British journal of clinical pharmacology.

[136]  J. Ham,et al.  Factors influencing hepatic glutathione concentrations: a study in surgical patients. , 1982, Clinical science.

[137]  D. Amacher,et al.  Tetracycline-induced steatosis in primary canine hepatocyte cultures. , 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[138]  Jörg Köhl,et al.  Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans , 2005, Nature Genetics.

[139]  M. Mittal,et al.  Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report , 2000, Annals of Internal Medicine.

[140]  H. Kim,et al.  Oxidative damages in the DNA, lipids, and proteins of rats exposed to isofluranes and alcohols. , 2006, Toxicology.

[141]  Neil Kaplowitz,et al.  Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. , 2006, JAMA.

[142]  J. Maher,et al.  Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis , 2014, Current Hepatology Reports.

[143]  A. T. Bentley,et al.  Inhibition of Mammalian Mitochondrial Protein Synthesis by Oxazolidinones , 2006, Antimicrobial Agents and Chemotherapy.

[144]  U. Christen,et al.  Mechanisms of halothane toxicity: novel insights. , 1993, Pharmacology & therapeutics.

[145]  B. Holtmann,et al.  Fulminant hepatic failure after repeated exposure to isoflurane anesthesia: A case report , 1991, Hepatology.

[146]  S. Knight,et al.  A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. , 2006, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[147]  Yongjie Ma,et al.  Dual Outcomes of Rosiglitazone Treatment on Fatty Liver , 2016, The AAPS Journal.

[148]  J. Reichen,et al.  Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. , 2007, Journal of hepatology.

[149]  H. Cortez‐Pinto,et al.  Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. , 1999, JAMA.

[150]  R. N. Macsween,et al.  Cirrhosis with steatohepatitis after adjuvant tamoxifen , 1999, The Lancet.

[151]  P. Tovo,et al.  Fulminant Hepatitis After 10 Days of Acetaminophen Treatment at Recommended Dosage in an Infant , 2011, Pediatrics.

[152]  P. Gual,et al.  Autophagy and Non-Alcoholic Fatty Liver Disease , 2014, BioMed research international.

[153]  J. Capeau,et al.  From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management , 2012, Current opinion in infectious diseases.

[154]  G. Davey Smith,et al.  Supplementary Tables , 2009 .

[155]  H. Bonkovsky,et al.  Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration , 2000, American Journal of Gastroenterology.

[156]  C. Tuquet,et al.  Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria , 2004, Cell Biology and Toxicology.

[157]  M. Molokhia,et al.  Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury , 2011, Clinical pharmacology and therapeutics.

[158]  A. Holt,et al.  Acute liver failure after administration of paracetamol at the maximum recommended daily dose in adults , 2010, BMJ : British Medical Journal.

[159]  R. Capaldi,et al.  Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. , 2007, Toxicology and applied pharmacology.

[160]  G. Tarantino,et al.  Silent non-alcoholic fatty liver disease-a clinical-histological study. , 2004, Journal of hepatology.

[161]  J. Bruce German,et al.  Lipid metabolome-wide effects of the PPARγ agonist rosiglitazones⃞s The online version of this article (available at http://www.jlr.org) contains an additional 4 tables. Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200169-JLR200 , 2002, Journal of Lipid Research.

[162]  A. Guillouzo,et al.  Induction of vesicular steatosis by amiodarone and tetracycline is associated with up‐regulation of lipogenic genes in heparg cells , 2011, Hepatology.

[163]  A. Lugea,et al.  Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. , 2011, Journal of hepatology.

[164]  F. Ruschitzka,et al.  Acetaminophen Increases Blood Pressure in Patients With Coronary Artery Disease , 2010, Circulation.

[165]  S. Cole,et al.  Antiretroviral Therapy Exposure and Insulin Resistance in the Women's Interagency HIV Study , 2008, Journal of acquired immune deficiency syndromes.

[166]  Mitchell R. McGill,et al.  Differences in Early Acetaminophen Hepatotoxicity between Obese ob/ob and db/db Mice , 2012, Journal of Pharmacology and Experimental Therapeutics.

[167]  I. Gradus-Pizlo,et al.  Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. , 2009, Journal of gastrointestinal and liver diseases : JGLD.

[168]  J. Custódio,et al.  Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. , 2001, Toxicology and applied pharmacology.

[169]  B. Neuschwander‐Tetri,et al.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.

[170]  H. Guchelaar,et al.  Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. , 2013, Pharmacogenomics.

[171]  M. Maes,et al.  Experimental models of hepatotoxicity related to acute liver failure. , 2016, Toxicology and applied pharmacology.

[172]  J. Hynes,et al.  A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[173]  B. Fromenty,et al.  Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice. , 2009, The American journal of pathology.

[174]  P. Ganey,et al.  Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[175]  M. Coen,et al.  Systems Level Metabolic Phenotype of Methotrexate Administration in the Context of Non-alcoholic Steatohepatitis in the Rat , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[176]  S. Binet,et al.  Evaluation of rat hepatic 2E1 activity in function of age, sex and inducers: choice of an experimental model capable of testing the hepatotoxicity of low molecular weight compounds. , 1999, Toxicology letters.

[177]  B. Fromenty,et al.  Adipocytes Targets and Actors in the Pathogenesis of HIV-Associated Lipodystrophy and Metabolic Alterations , 2004, Antiviral therapy.

[178]  O. Shibolet,et al.  Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease , 2015, BioMed research international.

[179]  T. Ikeda.  Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. , 2011, Drug metabolism and pharmacokinetics.

[180]  F. W. Hehre.  "Halothane hepatitis". , 1974, Connecticut medicine.

[181]  H. Canhão,et al.  Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity? , 2014, Immunologic Research.

[182]  G. Guo,et al.  Mechanistic review of drug-induced steatohepatitis. , 2015, Toxicology and applied pharmacology.

[183]  Min You,et al.  Ethanol administration exacerbates the abnormalities in hepatic lipid oxidation in genetically obese mice. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[184]  Ze-jun Li,et al.  Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria. , 2015, Toxicology and applied pharmacology.

[185]  P. Ritz,et al.  Kinetics and control of oxidative phosphorylation in rat liver mitochondria after dexamethasone treatment. , 2004, The Biochemical journal.

[186]  S. Sherlock,et al.  Halothane-related hepatitis. A clinical study of twenty-six cases. , 1976, The Quarterly journal of medicine.

[187]  R. Green,et al.  Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. , 2004, Journal of hepatology.

[188]  S. Raisuddin,et al.  Taurine prevents tamoxifen-induced mitochondrial oxidative damage in mice. , 2008, Basic & clinical pharmacology & toxicology.

[189]  D. Clegg,et al.  Acetaminophen normalizes glucose homeostasis in mouse models for diabetes. , 2008, Biochemical pharmacology.

[190]  D. Tuma,et al.  Methotrexate hepatotoxicity. , 1984, Journal of the American College of Nutrition.

[191]  J. Joven,et al.  Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study. , 2014, Journal of proteome research.

[192]  P. Eghtesadi-Araghi,et al.  Halothane hepatitis in Iran: a review of 59 cases. , 2008, World journal of gastroenterology.

[193]  Cheol-Young Park,et al.  Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease , 2013, Journal of diabetes investigation.

[194]  Jacqueline L. Beaudry,et al.  Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[195]  Mitchell R. McGill,et al.  Low Dose Acetaminophen Induces Reversible Mitochondrial Dysfunction Associated with Transient c-Jun N-Terminal Kinase Activation in Mouse Liver. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[196]  G. Gores,et al.  Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis[S] , 2016, Journal of Lipid Research.

[197]  E. Kharasch,et al.  Clinical isoflurane metabolism by cytochrome P450 2E1. , 1999, Anesthesiology.

[198]  T. Saphner,et al.  The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer , 2009, Cancer.

[199]  E. P. Dellinger,et al.  CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease , 2003, Hepatology.

[200]  J. González‐Gallego,et al.  Halothane induces oxidative stress and NF-kappaB activation in rat liver: protective effect of propofol. , 2006, Toxicology.

[201]  K. Kragballe,et al.  Methotrexate induced liver cirrhosis , 1980, The British journal of dermatology.

[202]  Wen Xie,et al.  Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator , 2014, Critical reviews in toxicology.

[203]  P. Valensi,et al.  Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation , 1998, Fundamental & clinical pharmacology.

[204]  J. Shelton,et al.  Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. , 2015, The Journal of clinical investigation.

[205]  M. T. Donato,et al.  Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[206]  L. E. B. Ttiger.  HALOTHANE-INDUCED LIVER DAMAGE: AN ANALYSIS OF THE MATERIAL REPORTED TO THE SWEDISH ADVERSE DRUG REACTION COMMITTEE, 1966???1973 , 1977 .

[207]  Mohammed Akbar,et al.  Translational Implications of the Alcohol-Metabolizing Enzymes, Including Cytochrome P450-2E1, in Alcoholic and Nonalcoholic Liver Disease. , 2015, Advances in pharmacology.

[208]  D. Malatjalian,et al.  Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. , 1996, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[209]  T. Iseli,et al.  Compound K modulates fatty acid‐induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[210]  M. Thursz,et al.  Prednisolone or Pentoxifylline for Alcoholic Hepatitis. , 2015, The New England journal of medicine.

[211]  You-Ming Li,et al.  Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. , 2014, World journal of gastroenterology.

[212]  Liang-Shang Gan,et al.  Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[213]  H. Iwaasa,et al.  Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[214]  S. Snyder,et al.  Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[215]  B. Fromenty,et al.  High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[216]  M. Athar,et al.  Catechin prevents tamoxifen-induced oxidative stress and biochemical perturbations in mice. , 2006, Toxicology.

[217]  G. Becker.  Fatty Acid Lessens Halothane's Inhibition of Energy Metabolism in Isolated Hepatocytes , 1990, Anesthesia and analgesia.

[218]  Kejian Wang,et al.  A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications , 2015, Oncotarget.

[219]  Michael Emmett,et al.  Acetaminophen toxicity and 5-oxoproline (pyroglutamic acid): a tale of two cycles, one an ATP-depleting futile cycle and the other a useful cycle. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[220]  A. J. Gandolfi,et al.  Halothane Biotransformation in Obese and Nonobese Patients , 1982, Anesthesiology.

[221]  D. Moore,et al.  The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism , 2000, Nature.

[222]  R. Ghose,et al.  Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. , 2015, Life Science.

[223]  I. Quesada,et al.  Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. , 2014, The Journal of endocrinology.

[224]  B. Fromenty,et al.  Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis , 2012, British journal of pharmacology.

[225]  B. Fromenty.  Drug-induced liver injury in obesity. , 2013, Journal of hepatology.

[226]  B. Fromenty,et al.  Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease , 2013, Hepatology.

[227]  M. Olschewski,et al.  Uridine Abrogates Mitochondrial Toxicity Related to Nucleoside Analogue Reverse Transcriptase Inhibitors in Hepg2 Cells , 2002, Antiviral therapy.

[228]  T. Trenti,et al.  Plasma glutathione level in paracetamol daily abuser patients. Changes in plasma cysteine and thiol groups after reduced glutathione administration. , 1992, Toxicology letters.

[229]  A. Bianco,et al.  Dexamethasone Reduces Energy Expenditure And Increases Susceptibility To Diet-Induced Obesity In Mice , 2013, Obesity.

[230]  D. Clegg,et al.  Over-the-counter analgesics normalize blood glucose and body composition in mice fed a high fat diet. , 2008, Biochemical pharmacology.

[231]  C. Fierbinţeanu-Braticevici,et al.  Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. , 2010, World journal of gastroenterology.

[232]  Mitchell R. McGill,et al.  Pathophysiological significance of c-jun N-terminal kinase in acetaminophen hepatotoxicity , 2015, Expert opinion on drug metabolism & toxicology.

[233]  William M. Lee,et al.  Drug‐induced acute liver failure: Results of a U.S. multicenter, prospective study , 2010, Hepatology.

[234]  B. Fromenty,et al.  Role of endoplasmic reticulum stress in drug‐induced toxicity , 2016, Pharmacology research & perspectives.

[235]  Y. Will,et al.  Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[236]  William M. Lee,et al.  Influence of high body mass index on outcome in acute liver failure. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[237]  A. Pardakhty,et al.  Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran , 2015, Hepatitis monthly.

[238]  N. Kitteringham,et al.  Metabolism of fluorine-containing drugs. , 2001, Annual review of pharmacology and toxicology.

[239]  J. Solís-Herruzo,et al.  In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis , 2014, Disease Models & Mechanisms.

[240]  Q. Whiting-O'Keefe,et al.  Methotrexate and histologic hepatic abnormalities: a meta-analysis. , 1991, The American journal of medicine.

[241]  R. Green,et al.  Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. , 2011, Annals of hepatology.

[242]  Guo-liang Zhang,et al.  Effect of berberine on hepatocyte proliferation, inducible nitric oxide synthase expression, cytochrome P450 2E1 and 1A2 activities in diethylnitrosamine- and phenobarbital-treated rats. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[243]  V. Johnson,et al.  Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[244]  Q. Anstee,et al.  Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. , 2016, Annual review of pathology.

[245]  P. Forget,et al.  Therapeutic dose of acetaminophen may induce fulminant hepatitis in the presence of risk factors: a report of two cases. , 2009, British journal of anaesthesia.

[246]  A. Kowaltowski,et al.  Effects of high fat diets on rodent liver bioenergetics and oxidative imbalance , 2016, Redox biology.

[247]  F. Bellanti,et al.  Free radical biology for medicine: learning from nonalcoholic fatty liver disease. , 2013, Free radical biology & medicine.

[248]  B. Erstad,et al.  Hepatotoxicity in Obese Versus Nonobese Patients With Acetaminophen Poisoning Who Are Treated With Intravenous N-Acetylcysteine , 2016, American journal of therapeutics.

[249]  D. Adams,et al.  Modeling idiosyncrasy: A novel animal model of drug‐induced liver injury , 2015, Hepatology.

[250]  William M. Lee,et al.  Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. , 2015, Gastroenterology.

[251]  M. Charlton,et al.  Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis , 2003, Hepatology.

[252]  E. Björnsson,et al.  Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports , 2016, Hepatology.

[253]  A. Phulukdaree,et al.  Mitochondrial and Oxidative Stress Response in HepG2 Cells Following Acute and Prolonged Exposure to Antiretroviral Drugs , 2015, Journal of cellular biochemistry.

[254]  S. Prey,et al.  Effect of folic or folinic acid supplementation on methotrexate‐associated safety and efficacy in inflammatory disease: a systematic review , 2009, The British journal of dermatology.

[255]  S. French,et al.  Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease , 2009, European journal of gastroenterology & hepatology.

[256]  R. Tubiana,et al.  Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus‐1 mono‐infected patients on antiretroviral therapy , 2009, Hepatology.

[257]  G. Maartens,et al.  Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug Reaction , 2013, PloS one.